The biology of signal transduction inhibition: Basic science to novel therapies

Seminars in Oncology

Volumn 28, Issue 5 SUPPL. 17, 2001, Pages 3-8

  Griffin, James ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MESYLIC ACID DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; CHRONIC MYELOID LEUKEMIA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GASTROINTESTINAL TUMOR; HUMAN; MULTIGENE FAMILY; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0035207448     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(01)90097-1     Document Type: Review

References (22)

1. A minute chromosome in human chronic granulocytic leukemia
2. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine, fluorescence and Giemsa staining
3. The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein
4. Mechanisms of transformation by the BCR/ABL oncogene
5. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines
6. Bcr/Abl activates transcription of the Bcl-X gene through STAT5
7. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-kinase/AKT pathway
8. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
9. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
10. The tyrosine kinase inhibitor CGP571488 selectively inhibits the growth of BCR-ABL-positive cells
11. ARG tyrosine kinase activity is inhibited by STI571
12. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors
13. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
14. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
15. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
16. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
17. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
18. Clinical resistance to STI-571 in cancer therapy caused by BCR-ABL gene mutation or amplification
19. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
20. Expression and functional role of the proto oncogene c-Kit in acute myeloblastic leukemia cells
21. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
22. Trisomy7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas